From Wikipedia, the free encyclopedia
Jump to: navigation, search

Zambon is an Italian pharmaceutical and fine chemical multinational company. Zambon is headquartered in Milan and was established in 1906 in Vicenza, where are based the Italian fine-chemical and pharma plants. Other manufacturing units are in Switzerland, France, China and Brazil. Zambon is present in 15 countries with more than 2,600 employees. It operates directly in Europe, South America and Asia.[citation needed]

The characteristic consolidated Group turnover is Euro 562 mio with a gross operating margin of Euro 80 mio. The turnover of the pharmaceutical business accounts for 84% and the chemical business for the remaining 16%. Italy represents a fifth of the overall turnover.[citation needed]


1906: On November 11, Gaetano Zambon with a pharmacy degree and various experiences in the trading of chemical products and spices, launched in Vicenza the activities of the "Zambon's medicines warehouse" together with Silvio Farina;[1]

1908: the company has been called "Gaetano Zambon & C.”;

1920: after the slowdown due to the First World War, the company started manufacturing activities of galenic drugs;

1928: The company turned into an industrial organization, with the brand ZEF, the names of the two partners: Gaetano Zambon and Silvio Farina;

1930: As the business continued to grow, an old factory of chemical fertilizers has been bought in Via Cappuccini, and after a significant restoration it became the new headquarters of the Company;

1933: Together with the drugs production began the activity of raw materials'synthesis

1944: On May 14, the Zambon Vincenza plant has been destroyed by American bombing

1946: Inauguration of the new Zambon Vicenza plant after the destruction of the historical site. The plant has become a real neighborhood in Vicenza, more modern and functional. The organization counted 550 employees, including 500 production workers and 50 researchers;

1948: Alberto Zambon, 24 years old, son of Gaetano, with a degrees in chemistry and pharmacy, joined the company to take the lead a few years later;

1951: The name of the company changed from "G. Zambon & C. SA" into "G. Zambon & C. SpA"

1956: Establishment of the first subsidiary in Brazil

1958: The collaborations with the big American pharmaceutical research companies started, including Parke Davis, which has proved to be crucial in the Zambon international development;

1959: Gaetano Zambon died when he was 81 years old. The company changed its name to Zambon SPA;

1960: Spanish subsidiary was founded;

1961: Foundation of Zambon Bresso site, with administrative offices and research laboratories, which would become the administrative center of the company since 1962. Relationships with Japan were created, through the partnership with EISAI, which brought to chloramphenicol injection production licence on Japanese territory;

1963: launch of the Swiss market;

1965: Fluimucil has been phased in the market for the first time;

1965-75: International development of the Group, which opened its subsidiaries in major European countries and in Central and South America;

1970: the new "avantgarde" plant for chemical activities has been built in Almisano Lonigo(Vicenza;

1979: The research identified a new molecule Zambon (Fosfomycin trometamol) to trade into the market (Monuril);

1983: Acquisition of the pharmaceutical industry SIMES Milan, founded by Emilio Giordano Ghirardi, father of Alberto Zambon;

1984: the Pharmaceutical production has been transferred to a new and more efficient plant in Via della Chimica, in the industrial area of Vicenza;

1985: Zambon research identified a new molecule (Ibuprofen + Arginine) to trade into market (Spidifen);

1995: Zambon spread to the east, with the opening of its branches in Russia and Hong Kong and the launch of the first joint venture in China;

1999: The family Zambon divided the capital stock and operational roles: the head of the Group has been committed to a CEO who was not part of the family;

2000: Agreements with several international pharmaceutical companies for the trading of Zambon spin-offs molecules and for the production of raw materials and generics. Inauguration of the Chinese factory to support the local market;

2002: Opening of the subsidiary in India;

2003: Z-Cube was born, an incubator for new drug discovering technologies.

2006: Zambon celebrated in the 15 countries in which it operates, the centenary of the foundation;

2007: It launched its new corporate structure that involves the separation of pharma activities from those of fine chemicals, concentrated in two independent and autonomous entities: Zambon Pharma and Zach System. Due to this separation has been created the holding company, Zambon Company, with the role of strategic planning and monitoring of the economic performance of the group. In the same time Zoé - Zambon Open Education - a foundation that aims to develop a culture of health and quality of life was born;[citation needed]

2008: Zambon Museum was born


Zambon Company S.p.A. is the industrial holding of the group, with Zach (Zambon Chemicals) which is a preferred partner for API, Custom synthesis and generics products for big pharma companies; with Zambon S.p.A., the pharma business, which mainly operates in respiratory, pain and women healthcare; with Z-Cube, the corporate research venture, scouting new technologies and drug delivery system opportunities. Thanks to privileged relations with the scientific international community, Zambon has created “Open Zone”, a research and innovation Scientific Campus in Bresso (Milan).[citation needed]


Zambon's leading brands are Fluimucil, Monuril, and Spididol.